|
|
|
|
|
|
| ||||
Last Loaded on Web: Wednesday, July 01, 2009
Drug Information Fulltext corresponds to two printed publications: The American Hospital Formulary Service, which contains information on 1,000 drugs available commercially in the United States, and The Handbook on Injectable Drugs, which covers 217 commercially available and 57 investigational drugs in use in the U.S. Drug Information Fulltext may be searched for information on the stability, chemistry, and pharmaco-kinetics of drugs, as well as on their action, usage, dosage, and administration. The file also covers compatibility and interactions of drugs and cautions for use.
DIF, through controlled indexing terms and related numerical concept codes, makes it possible to search and display complete monographs, sections of monographs, primary text, additional text, tables, references and/or footnotes. Records for an individual drug include trade names, generic name, manufacturer, CAS® (Chemical Abstracts Service) Registry Number, therapeutic classification, and textual information in the following subject areas:
Sections and subsections include information further divided on a wide range of topics, including such areas as the following:
The monographs from the AHFS (American Hospital Formulary Service) Drug Information and the Handbook On Injectable Drugs, which are the nucleus of DIF, are written after extensive examination of the literature (references are indicated) and are reviewed by an expert panel. The result is an evaluative monograph discussing the manufacturer's claims and actual clinical experience for each drug.
| Dates Covered: | 2002 |
|---|---|
| File Size: | 1,523 records |
| Update Frequency: | Closed |
| ACRONYM | CATEGORY NAME |
|---|---|
| BRANDNMS | Brand Names |
| CASREGNO | CAS(R) Registry Numbers-Chemical and Medical Files |
| DRUGDIR | Drug Directories |
| PHARM | Pharmacology |
| PHARMR | Pharmacology + RINGDOC-Files |
| RNMED | CAS(R) Registry Numbers - Medical Files |
| SAFETY | Safety |
| TOXICOL | Toxicology |
|
Drug Information Fulltext is produced by the American Society of Health-System Pharmacists. Questions concerning file content should be directed to: Emily Morris 7272 Wisconsin Avenue Bethesda, MD 20814
|
For Dialog's Redistribution and Archive Policy, enter HELP ERA online. The following terms and conditions also apply.
Drug Information Fulltext (File 229) The American Society of Health-System Pharmacists represents that the database provided hereunder was formulated with a reasonable standard of care, and in conformance to professional standards in the field. Except with respect to the foregoing and as otherwise specifically provided in this agreement, the American Society of Health-System Pharmacists makes no representations or warranties, express or implied, including but not limited to, any implied warranty of merchantability or fitness for a particular purpose, with respect to such database and specifically disclaims all such warranties and representations. Users are advised that decisions regarding drug therapy are the responsibility of the clinician; and that this file (DIF) is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses, and side effects.
| DIALOG(R)File 229:Drug Info. Fulltext | |
| (c) 2002 Ameri.Soc.of Health-Systems Pharm. All rts. reserv. | |
| AH=,/SH | 00998967 AHFS NO: 84.06 AHFS CLASS: Anti-inflammatory Agents |
| SF= | SUBFILE: AHFS Drug Information |
| MT=,/NA | MONOGRAPH TITLE: Clobetasol Propionate |
| GN=,/NA | GENERIC NAME: Clobetasol Propionate |
| MF= | MOLECULAR FORMULA: C25H32ClFO5 |
| SY=,/TN | SYNONYMS: Clobetasol 17-Propionate |
| IN= | INVESTIGATIONAL NO: CCI 4725; GR 2/925 |
| /TN,TN=,MN= | BRAND NAME/MANUFACTURER: Embeline E/Healthpoint; Temovate E/ |
| GlaxoSmithKline; Olux/Connetics; Clobevate/Stiefel; Cormax/Oclassen; | |
| Temovate/GlaxoSmithKline; Cormax Scalp Application/Oclassen; Temovate Scalp | |
| Application/GlaxoSmithKline | |
| RN= | CAS REGISTRY NO: 25122-46-7 |
| /SH | CHEMISTRY AND STABILITY (CH): |
| PRIMARY TEXT: | |
| /SH | Chemistry |
| /CH,/TX | [3115] Clobetasol propionate is a synthetic fluorinated |
| corticosteroid.(1,88) [3135,3145] The drug occurs as a white to | |
| cream-colored, crystalline powder,(1,2,88) is odorless,(2,88) and has | |
| solubilities of 2 mcg/mL in water at room temperature(1,2,88) and 10 mg/mL | |
| in alcohol.(2) | |
| /SH | Stability |
| /CH,/TX | [3345] Clobetasol propionate cream, ointment, and gel should be stored at |
| 15-30DGC; the cream should not be refrigerated.(1,87) Clobetasol propionate | |
| solution should be stored at 4-25DGC; the solution should not be used near | |
| an open flame.(80) Clobetasol propionate foam should be stored at a | |
| controlled room temperature between 20-25DGC, and exposure to temperatures | |
| warmer than 49DGC should be avoided.(88) Because the contents of the foam | |
| are under pressure, the container should not be punctured, used or stored | |
| near heat or an open flame, or placed into a fire or incinerator for | |
| disposal.(88) | |
| ADDITIONAL TEXT: CHEMISTRY AND STABILITY | |
| /SH | Stability |
| /CH,/TX | [3900] For further information on chemistry, pharmacology, absorption, |
| uses, cautions, and methods of application of clobetasol propionate, see | |
| the Topical Corticosteroids General Statement 84:06. | |
| PHARMACOKINETICS (PK): | |
| PRIMARY TEXT: | |
| /SH | Absorption |
| /PK,/TX | [3815] Percutaneous penetration of clobetasol propionate varies among |
| individuals(5,33-35,41,42,61,66,67,69,70) and can be altered by using | |
| different vehicles;(1,7,18,22,30,31,41,43,67,69,71,73,88) percutaneous | |
| penetration can be increased by the use of occlusive | |
| dressings(1,7,8,18,22,62,69,70,72,88) and by inflammation and/or other | |
| diseases of the epidermal barrier (e.g., psoriasis, | |
| eczema).(1,18,62,66,70-73,88) | |
| [3815] Following topical application of clobetasol propionate to most | |
| areas of normal skin, only small amounts of the drug appear to reach the | |
| dermis(66) and subsequently the systemic circulation with the usual | |
| dosage;(61,66,67) however, systemic absorption may be increased when the | |
| usual dosage is exceeded(3,7,11,13,46,59,61,64,79) or when the skin is | |
| inflamed or diseased.(1,18,59,62,66,70,72,73) [3855,3815] Mean peak plasma | |
| clobetasol propionate concentrations of 0.63 ng/mL occurred in one study 8 | |
| hours after a second 30-g dose (applied 13 hours after an initial dose) of | |
| clobetasol propionate 0.05% ointment in healthy individuals with normal | |
| skin; mean peak plasma concentrations of the drug were slightly higher and | |
| occurred 10 hours after the second dose when the 0.05% cream was | |
| employed.(67) Mean peak plasma concentrations of approximately 2.3 or 4.6 | |
| ng/mL occurred in another study about 3 hours after a single application of | |
| a 25-g dose of a 0.05% ointment in patients with psoriasis or eczema, | |
| respectively.(66) | |
| /SH | Elimination |
| /PK,/TX | [3835] Following percutaneous penetration of clobetasol propionate, drug |
| that is systemically absorbed probably follows the metabolic pathways of | |
| systemically administered corticosteroids.(1,76,88) (See Pharmacokinetics: | |
| Elimination, in the Corticosteroids General Statement 68:04.) However, | |
| systemic metabolism of clobetasol has not been fully characterized or | |
| quantified.(76) Clobetasol and its metabolites are excreted in bile(1,76) | |
| and in urine(76) in animals. | |
| /SH | USES (US): |
| USES | |
| /US,/TX | [3225] Clobetasol propionate shares the actions of other topical |
| corticosteroids and is used for the short-term relief of the inflammatory | |
| and pruritic manifestations of moderate to severe corticosteroid-responsive | |
| dermatoses, including dermatoses of the scalp.(1,3-29,32,74,78,81-86,88) | |
| /SH | CAUTIONS (CA): |
| PRIMARY TEXT: | |
| /CA,/TX | [3605,3645,3525,3575] Clobetasol propionate preparations are some of the |
| most potent topical corticosteroid preparations currently | |
| available.(33-45,88) Because of its potency, the drug can suppress the | |
| hypothalamic-pituitary-adrenal (HPA) axis following topical | |
| application,(3,7,11-13,17-20,26,27,46,55,57,59,61,62,64,88) and HPA-axis | |
| suppression has occurred following topical dosages as low as 2 g of the | |
| 0.05% ointment or cream (1 mg of clobetasol propionate total) or 7 g of the | |
| 0.05% foam (3.5 mg of clobetasol propionate total) or 7 g of the 0.05% foam | |
| (3.5 mg of clobetasol propionate total) daily.(1,76,88) Because of the | |
| drug's potency and potential for causing adverse systemic effects during | |
| topical therapy, the usual dosage should not be exceeded and occlusive | |
| dressings (including bandages) should not be applied to areas of clobetasol | |
| propionate application.(1) (See Dosage and Administration.) | |
| [3605] Pustules on the scalp, tingling, folliculitis, tightening of the | |
| scalp, tenderness, dermatitis, alopecia, and headache may occur in some | |
| patients receiving clobetasol propionate solution applied to the scalp.(80) | |
| Eye irritation also may occur if clobetasol propionate solution comes in | |
| contact with the eye(s); if such contact occurs, the affected eye(s) should | |
| be flushed with copious amounts of water.(80-83) | |
| [3645,3225] Like other topical corticosteroids, clobetasol should not be | |
| used in the treatment of acne,(1,6,18) rosacea,(1,6,18) or perioral | |
| dermatitis,(1) or as monotherapy in the treatment of widespread plaque | |
| psoriasis.(1) [3645,3625] The manufacturers state that clobetasol | |
| propionate preparations are contraindicated in individuals with known | |
| hypersensitivity to the drug, other corticosteroids, or any ingredient in | |
| the respective formulation.(1,88) | |
| [3645,3225] If concomitant skin infections develop during clobetasol | |
| therapy, appropriate antifungal or antibacterial therapy should be | |
| initiated; if the infection does not respond promptly to such therapy, | |
| clobetasol should be discontinued until the infection has been controlled | |
| adequately.(1,80,87,88) | |
| [3645] The manufacturer of clobetasol propionate foam states that if | |
| irritation occurs during treatment, the drug should be discontinued and | |
| appropriate therapy instituted.(88) | |
| /SH | Geriatric Precautions |
| /CA,/TX | [3645,3255] Clinical studies of clobetasol propionate foam did not |
| include sufficient numbers of patients 65 years of age and older to | |
| determine whether geriatric patients respond differently than younger | |
| patients.(88) While other clinical experience has not revealed age-related | |
| differences in response, drug dosage generally should be titrated carefully | |
| in geriatric patients, usually initiating therapy at the low end of the | |
| dosage range.(88) The greater frequency of decreased hepatic, renal, or | |
| cardiac function and of concomitant disease and drug therapy observed in | |
| the elderly also should be considered.(88) | |
| /SH | Mutagenicity and Carcinogenicity |
| /CA,/TX | [3665,3003] No evidence of clobetasol-induced mutagenesis was seen in |
| various in vitro microbial test systems (e.g., Ames test) with or without | |
| metabolic activation.(76) [3665] Long-term studies to determine the | |
| carcinogenic potential of topical corticosteroids have not been performed | |
| to date.(1,88) | |
| /SH | Pregnancy, Fertility, and Lactation |
| /CA,/TX | [3655] The teratogenic potential of topical clobetasol propionate is not |
| known;(88) however, the drug appears to undergo percutaneous absorption, | |
| and reproduction studies in mice and rabbits using subcutaneous dosages of | |
| the drug up to 1 mg/kg and 10 mcg/kg daily, respectively, have revealed | |
| evidence of substantial harm to the fetus (e.g., cleft palate, skeletal | |
| immaturity, increased stillbirths and fetal resorptions).(1,76,88) | |
| Teratogenic effects of clobetasol were observed at subcutaneous dosages | |
| about one-fourth to one-twelfth those of betamethasone in these | |
| animals.(76,88) [3655,3003] In addition, although the teratogenic potential | |
| of topical clobetasol has not been studied, other potent corticosteroids | |
| have been shown to be teratogenic in animals following topical | |
| application.(1) [3655,3905] For additional information, see Cautions: | |
| Pregnancy, Fertility, and Lactation, in the Topical Corticosteroids General | |
| Statement 84:06. | |
| /SH | ADDITIONAL TEXT: CAUTIONS |
| /CH,/TX | Clobetasol propionate shares the toxic potentials of other topical |
| corticosteroids,(1,3,7,11-14,17,19-22,26,27,46-65,78,79) and the usual | |
| precautions of corticosteroid therapy should be observed.(1,3,46) (See | |
| Cautions in the Topical Corticosteroids General Statement 84:06.) | |
| /SH | DOSAGE AND ADMINISTRATION (DO): |
| PRIMARY TEXT: | |
| /DO,/TX | [3575,3525] Topical clobetasol propionate cream, ointment, and gel are |
| applied sparingly in thin films and are rubbed gently into the affected | |
| area twice daily, preferably in the morning and evening.(1,87) Clobetasol | |
| propionate foam and solution are applied to affected areas of the scalp | |
| twice daily, in the morning and evening.(80,81,84,88) Clobetasol propionate | |
| foam is flammable; therefore, exposure to flames or smoking should be | |
| avoided during and immediately after application.(88) When clobetasol | |
| propionate foam is applied, the canister containing the drug should be | |
| inverted and a small amount (up to a maximum of a golf-ball-sized dollop) | |
| of the preparation placed into the cap of the canister, onto a saucer, or | |
| other cool surface, or directly on the lesion, taking care to avoid contact | |
| with the eyes.(88) The foam should not be dispensed directly to the hands, | |
| since the foam will begin to melt immediately upon contact with warm | |
| skin.(88) Hair should be moved away from the affected area of the scalp to | |
| allow application of the drug onto each affected area.(88) The drug should | |
| be massaged gently into the affected scalp until the foam disappears; | |
| repeat until the entire affected area has been treated.(88) | |
| Some patients may respond initially to once-daily(66) or intermittent | |
| therapy (e.g., twice daily 3 days per week).(29) [3525,3645] Clobetasol | |
| therapy should be discontinued and a less potent topical corticosteroid | |
| preparation substituted as soon as clinically feasible,(77) but dosage | |
| should not exceed 50 g of clobetasol propionate 0.05% cream, foam, or | |
| ointment or 50 mL of clobetasol propionate 0.05% lotion (25 mg of the drug | |
| total) per week, and duration of a course of clobetasol therapy generally | |
| should not exceed 14 days.(1,77,80,88) [3525,3645,3215] Many clinicians | |
| indicate that more prolonged clobetasol therapy rarely may be necessary in | |
| patients with resistant conditions,(3,5,6,9,10,12-14,16,20,21,23,24,27,29,3 | |
| 2,74,75,77) but careful monitoring is essential.(75,77) The risk of adverse | |
| systemic corticosteroid effects (e.g., HPA-axis suppression, Cushing's | |
| syndrome, hyperglycemia) associated with use of this potent corticosteroid | |
| must be carefully considered.(1,88) Intermittent maintenance therapy, such | |
| as administration of the drug once-(12) or twice-weekly(20,21) for up to 6 | |
| months, has resulted in prolonged periods of remission from | |
| corticosteroid-responsive dermatoses in some patients.(12,20,21) | |
| [3575,3645] Clobetasol propionate cream, foam, gel, ointment, or solution | |
| should not be used with occlusive dressings and patients should be warned | |
| that treated areas of the skin should not be bandaged or otherwise covered | |
| or wrapped as to be occlusive.(1,80,87,88) | |
| /SH | PREPARATIONS (PR): |
| PRIMARY TEXT: | |
| /PR,/TX | Clobetasol Propionate |
| [3474] Topical | |
| [3434] Cream | |
| [3436] 0.05%* | |
| [1050,3403] Cormax ([3413] with propylene glycol and parabens) | |
| [1080,3403] Oclassen | |
| [1050,3403] Embeline E (with propylene glycol) | |
| [1080,3403] Healthpoint | |
| [1050,3403] Temovate ([3413] with propylene glycol) | |
| [1080,3403] GlaxoSmithKline | |
| [1050,3403] Temovate E ([3413] with propylene glycol) | |
| [1080,3403] GlaxoSmithKline | |
| [3434] Foam | |
| [3436] 0.05% | |
| [1050,3403] Olux (with propylene glycol) | |
| [1080,3403] Connetics | |
| [3434] Gel | |
| [3436] 0.05%* | |
| [1050,3403] Clobevate ([3413] with propylene glycol) | |
| [1080,3403] Stiefel | |
| [1050,3403] Temovate ([3413] with propylene glycol) | |
| [1080,3403] GlaxoSmithKline | |
| [3434] Ointment | |
| [3436] 0.05%* | |
| [1050,3403] Cormax ([3413] with propylene glycol) | |
| [1080,3403] Oclassen | |
| [1050,3403] Temovate ([3413] with propylene glycol) | |
| [1080,3403] GlaxoSmithKline | |
| [3434] Solution | |
| [3436] 0.05%* | |
| [1050,3403] Cormax Scalp Application ([3413] with isopropyl alcohol 40% | |
| w/w) | |
| [1080,3403] Oclassen | |
| [1050,3403] Temovate Scalp Application ([3413] with isopropyl alcohol | |
| 39.3%) | |
| [1080,3403] GlaxoSmithKline | |
| INTRODUCTION | |
| [3115,3205] Clobetasol propionate is a synthetic fluorinated | |
| corticosteroid.(1) | |
| /SH | REFERENCES (RF): |
| /RF,/TX | 1. Glaxo Derm. Temovate (clobetasol propionate) cream and ointment |
| prescribing information. Research Triangle Park, NC; 1989 Oct. | |
| 2. Reynolds JEF, ed. Martindale: the extra pharmacopoeia. 28th ed. | |
| London: The Pharmaceutical Press; 1982:463-4. | |
| 3. Allenby CF, Main RA, Marsden RA et al. Effect on adrenal function of | |
| topically applied clobetasol propionate (Dermovate). Br Med J. 1975; | |
| 4:619-21. (IDIS 60244) | |
| (...) | |
| 84. Lassus A. Local treatment of psoriasis of the scalp with clobetasol | |
| propionate in alcoholic solution: a comparison of once and twice a day | |
| application. Curr Med Res Opin. 1976; 4:214-7. | |
| 85. Zar E. Topical clobetasol propionate in the treatment of scalp | |
| psoriasis: a medium term follow-up. Curr Ther Res. 1980; 28:997-1001. | |
| 86. Roduner J, Krebs A. [Dermovate scalp application in dermatologic | |
| practice: a multi-centre study covering the whole of Switzerland.] (German; | |
| translation supplied by Glaxo Dermatology.) Ther Umsch. 1980; 37:589-94. | |
| 87. Glaxo Dermatology. Temovate (clobetasol propionate) gel prescribing | |
| information. Research Triangle Park, NC; 1994 Jan. | |
| 88. Connetics Corporation. Olux foam 0.05% (clobetasol propionate) | |
| prescribing information. Palo Alto, CA; 2000 Sep. | |
| Selected Revisions January 2002, (C) Copyright, June 1986, | |
| AmericanSociety of Health-System Pharmacists, Inc. | |
| TABLES: | |
| [3403] *available by nonproprietary name | |
| DC=,/DE | DESCRIPTORS: [3115] Chemical description; [3205] Pharmacology; [3225] |
| Therapy; [3215] Unlabeled or investigational use; [3525] Dosage schedule; | |
| [3575] Administration route; [3645] Precaution contraindication; [3003] | |
| Other drug; [3225] Therapy; [3255] Age effect; [3525] Dosage schedule; | |
| [3575] Administration route; [3605] Adverse reaction (side effect); [3625] | |
| Sensitivity photosensitivity allergy; [3645] Precaution contraindication; | |
| [3655] Fetal toxicity; [3665] Carcinogenicity mutagenicity; [3815] | |
| Absorption; [3835] Elimination; [3855] Blood CSF level; [3115] Chemical | |
| description; [3135] Physical description; [3145] Solubility; [3345] Storage | |
| ; [3403] Preparations; [3413] Other chemical ion ingredient; [3434] Dosage | |
| form; [3436] Strength concentration |
| SEARCH SUFFIX |
DISPLAY CODE |
FIELD NAME |
INDEXING |
SELECT EXAMPLES |
|---|---|---|---|---|
| None | None | All Basic Index Fields | Word | S CALCIUM(1W)BLOCK? |
| /DE | DE | Descriptor1 | Word & Phrase |
S DOSAGE(W)SCHEDULE/DE S BLOOD CSF LEVEL/DE |
| /NA | NA | Generic Name, Monograph Title4 | Word & Phrase |
S CLOBETASOL(W)PROPIONATE/NA S CLOBETASOL PROPIONATE/NA |
| /SH | SH | AHFS Drug Classification, Section, and Subsection Heading | Word & Phrase |
S ANTI(W)INFLAMMATORY/SH S ANTI-INFLAMMATORY AGENTS/SH |
| /TN | TN | Trade Name, Synonym5 | Word & Phrase |
S TEMOVATE/TN S CLOBETASOL 17-PROPIONATE/TN |
| /TX | TX | Text (from all monograph sections) | Word | S CRYSTALLINE(W)POWDER(F)WHITE/TX |
| MONOGRAPH and SERIALS RECORDS | ||||
| /CA | CA | Cautions | Word | S HPA(W)AXIS(F)SUPPRESS?/CA |
| /CH | CH | Chemistry and Stability | Word | S FLUORINATED(W)CORTICOSTEROID?/CH |
| /CI | CI | Compatibility Information2 | Word | S ACIDIC(F)SOLUBILIT?/CI |
| /CI | TA | Compatibility Tables2 | Word | S DEXTROSE(W)CONCENTRATION/CI |
| /CT | CT | Concentration2 | Word | S STERILE(W)WATER(F)RECONSTITUT?/CT |
| /DI | DI | Drug Interactions | Word | S ALCOHOL(F)ANTIHISTAMINE?/DI |
| /DO | DO | Dosage and Administration | Word | S OCCLUSIVE(W)DRESSING?/DO |
| /LI | LI | Laboratory Test Interferences | Word | S PREGNANCY(W)TEST?/LI |
| /MA | MA | Mechanism of Action | Word | S DNA(W)SYNTHESIS(F)INHIBIT?/MA |
| /OT | OT | Other Information2 | Word | S LOW(W)ARTERIAL(W)PH/OT |
| /PC | PC | Pharmacology | Word | S CALCIUM(1W)BLOCK?/PC |
| /PH | PH | pH2 | Word | S 5(W)1/PH |
| /PK | PK | Pharmacokinetics | Word | S PERCUTANEOUS(W)PENETRATION/PK |
| /PR | PR | Preparations | Word | S TOPICAL(F)TEMOVATE/PR |
| /RE | RE | Resistance | Word | S MALIGNANT(W)CELL?/RE |
| /RF | RF | References | Word | S ALLENBY(W)CF/RF |
| /SP | SP | Spectrum | Word | S ANTIVIRAL(W)ACTIVIT?/SP |
| /TO | TO | Chronic Toxicity, Acute Toxicity | Word | S OVERDOS?(F)SEIZURE/TO |
| /US | US | Uses | Word | S CORTICOSTEROID(F)DERMATOSES/US |
3 These fields occur infrequently.
4 Also searchable separately in the Additional Indexes as GN= and MT=
5 Also searchable in the Additional Indexes as TN=
| SEARCH PREFIX |
DISPLAY CODE |
FIELD NAME |
INDEXING |
SELECT EXAMPLES |
|---|---|---|---|---|
| AH= | AH | AHFS Classification Number | Phrase | S AH=84.06 |
| None | AN | DIALOG Accession Number | ||
| CN= | CN | Chemical Name3 | Phrase | S CN=10-UNDECENOIC ACID |
| DC= | None | Descriptor Code | Phrase | S DC=3115 |
| GN= | GN | Generic Name | Word & Phrase |
S GN=(GLOBETALOL(W)PROPIONATE) S GN=CLOBETASOL PROPIONATE |
| IN= | IN | Investigational Drug Number3 | Word & Phrase |
S IN=ABBOTTS S IN=ABBOTT-50711 |
| MF= | MF | Molecular Formula3 | Phrase | S MF=C25H32CLFO5 |
| MN= | MN | Manufacturer | Word & Phrase |
S MN=GLAXO S MN=WARNER-LAMBERT |
| MT= | MT | Monograph Title | Word & Phrase |
S MT=(CLOBESASOL(W)PROPIONATE) S MT=CLOBETASOL PROPIONATE |
| RN= | RN | CAS(R) Registry Number | Phrase | S RN=25122-46-7 |
| SF= | SF | Subfile | Word & Phrase |
S SF=FORMULARY S SF=HANDBOOK OF INJECTABLE DRUGS? |
| SY= | SY | Synonym3 | Word & Phrase |
S SY=(CLOBETASOL(W)PROPIONATE) S SY=CLOBETASOL 17-PROPIONATE |
| TN= | TN | Tradename/Proprietary Name | Word & Phrase |
S TN=TEMOVATE S TN=METAMUCIL SUGAR FREE |
| UD= | None | Update | Phrase | S UD=9999 |
| Sets and terms may be restricted by Basic Indes suffixes, i.e., /DE, /DF, /NA, /SH, /TI, /TN, /TX, also /CA, /CH, /CI, /CT, /DI, /DO,/LI, /MA, /OT, /PC, /PH, /PK, /PR, /RE, /RF, /SP, /TO, and /US (e.g., S S5/NA). | ||
| SUFFIX | FIELD NAME | EXAMPLES |
|---|---|---|
| /FORM | AHFS Drug Information Records | S S2/FORM |
| /HANDBOOK | Handbook on Injectable Drugs Records | S S2/HANDBOOK |
| /NOTABLE | Records without Tabular Data | S S4/NOTABLE |
| /TABLE | Records with Tabular Data | S S4/TABLE |
| SORTABLE FIELDS | EXAMPLES |
|---|---|
| AH, GN | SORT S13/ALL/GN PRINT S5/5/1-24/AH/GN |
| RANK FIELDS | EXAMPLES |
|---|---|
| All phrase- and numeric-indexed fields in the Additional Indexes can be ranked. Other RANK codes include: DE, NA | RANK DE RANK MN S4 |
| MAP FIELDS | EXAMPLES |
|---|---|
| NA, RN, SY | MAP RN TEMP S2 |
| Display codes listed in the Search Options tables can be used to customize output. | TYPE S3/NA,SH,TN,RN/1-5 |
| NO. |
DIALOGWEB FORMAT |
RECORD CONTENT |
|---|---|---|
| 1 | -- | DIALOG Accession Number |
| 2 | -- | Full Record except Tables |
| 3 | Medium | AHFS Class Number and Name, Subfile, Monograph Title, Generic Name, Trade Name, Section Titles, CAS Registry Number |
| 4 | -- | AHFS Class Number and Name, Subfile, Monograph Title, Generic Name, Text (all) |
| 5 | Long | Full Record |
| 6 | Free | Subfile, Monograph Title, Generic Name, Section Titles |
| 7 | -- | AHFS Class Number and Name, Subfile, Monograph Title, Generic Name, Trade Name, Section Titles, CAS Registry Number, Descriptors |
| 8 | Short | AHFS Class Number and Name, Subfile, Monograph Title, Descriptors, Subsections |
| 9 | Full | Full Record |
| K | -- | KWIC (Key Word In Context) displays a window of text; may be used alone or with other formats |
| FIELD NAME | EXAMPLES | ||
|---|---|---|---|
| If the accession number of a specific record is known, it can be used to display the record directly. | TYPE 1998816/5 DISPLAY 1998775/MT,TN PRINT 1998999/5 |
||
Add RSS
Rates For File: Drug Information Fulltext[229]
Cost per DialUnit: $3.04
Cost per minute: $1.06
Rank Elements $0.00
Format Types Prints
1 $0.00 $0.00
2 $8.27 $8.27
3 $4.19 $4.19
4 $8.27 $8.27
5 $8.27 $8.27
6 $0.00 $0.00
7 $4.19 $4.19
8 $0.00 $0.00
9 $8.27 $8.27
19 $8.27 $8.27
KWIC95 $0.64 NA
KWIC96 $0.64 NA
REDIST/COPY Multiplier Table:
Range Multiplier
1-2 1.00
3-25 1.50
26-100 3.00
101-200 4.00
201-500 6.00
501-1000 8.00
1001 or more 10.00
ARCHIVE Multiplier Table:
Range Multiplier
1-25 1.50
26-200 3.00
201-500 6.00
501-1000 8.00
1001 or more 10.00
